DMRA — Damora Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1800315 ·
Last close
$25.89
Market Cap
$1.59B
52W High
$31.86
52W Low
$16.50
ADV30
312,691
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -30,811,000 | -27,783,000 | 535,442,000 | 532,899,000 | 23,839,000 |
| Dec 2025 | 0 | — | -201,696,000 | -200,736,000 | 260,527,000 | 257,624,000 | 20,147,000 |
| Sep 2025 | 0 | — | -3,156,000 | -3,133,000 | 10,736,000 | 7,606,000 | 2,729,000 |
| Jun 2025 | 0 | — | -3,421,000 | -3,437,000 | 13,691,000 | 10,211,000 | 2,738,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,726,000
Investing CF
$-17,374,000
Financing CF
$0
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-10.27
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-487,363,000
Inventory
—
Receivables
$899,000
ST Investments
$0
EBIT TTM
$-210,872,000
Pretax Income TTM
$-209,789,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -210,872,000 | -209,839,000 | 260,527,000 | 20,147,000 | — | -6,726,000 |
| Dec 2024 | 0 | -21,292,000 | -21,439,000 | 17,132,000 | 1,301,000 | — | -18,623,000 |
| Dec 2023 | 0 | -36,457,000 | -38,349,000 | 38,227,000 | 5,896,000 | — | -36,911,000 |
| Dec 2022 | 0 | -61,207,000 | -61,624,000 | 73,188,000 | 11,435,000 | — | -42,932,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.10
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GHRS | GH Research PLC | $1.59B | $23.15 | — |
| QURE | uniQure N.V. | $1.59B | $25.15 | — |
| ATAI | AtaiBeckley Inc. | $1.58B | $4.29 | — |
| ABCL | AbCellera Biologics Inc. | $1.62B | $5.29 | — |
| NUVB | Nuvation Bio Inc. | $1.63B | $4.69 | — |
News headlines (Yahoo Finance, 1h cache)
Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-12 20:05 · Yahoo
What Damora Therapeutics (DMRA)'s CEO Shake-Up and Finance Refresh Means For Shareholders
2026-05-08 21:30 · Yahoo
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer
2026-05-05 17:05 · Yahoo
Assessing Damora Therapeutics (DMRA) Valuation After CFO Transition And Recent Share Price Momentum
2026-05-05 14:10 · Yahoo
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 12:00 · Yahoo
Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says
2026-04-24 15:54 · Yahoo
What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?
2026-04-20 16:00 · Yahoo
How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%
2026-04-10 13:55 · Yahoo
Damora Therapeutics (DMRA) Overhauls Leadership: Is Its Capital Strategy About To Quietly Shift?
2026-04-01 12:18 · Yahoo
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
2026-03-23 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.